In this study, we examined the interplay between racial backgrounds and gene rearrangements or fusions involving BCL2, BCL6, and MYC in patients with DLBCL to enhance understanding of their roles in disease pathogenesis and clinical outcomes, with the goal of advancing personalized diagnostic and therapeutic approaches for improved outcomes. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.